Hematology
Gene therapies. Rebalancing agents. Complement-targeted biologics. Hematology is navigating decisions that did not exist five years ago, and the commercial stakes have never been higher.
Subscribe for Hematology updates
About Hematology
Hematology has moved from a steady-state market to a genuine inflection point. Gene therapies in sickle cell disease and beta-thalassemia, rebalancing agents reshaping hemophilia management, and the next wave of complement-targeted therapies in PNH are forcing physicians, payers, and patients to navigate treatment decisions of extraordinary complexity and consequence, decisions where expert-driven market intelligence is not optional.
Spherix’s hematology franchise is built on the same screening and governance standards used in markets Spherix has tracked for over a decade. Access to the right voices in hematology is not a given – these are small, highly specialized prescriber populations where panel quality matters more than panel size. The Spherix hematology community is built around verified, actively practicing hematologists and the KOLs who shape category opinion, backed by a fully dedicated team and a research program recognized for excellence at the International PNH Interest Group Scientific Conference, European Hematology Association, and the Bleeding Disorders Conference.
INDICATIONS COVERED
Bleeding disorders including:
- Women, Girls, and People Who Menstruate (WGPPM) with Bleeding Disorders
- Hemophilia A & B
- Von Willebrand Disease (VWD)
- Immune Thrombocytopenic Purpura (ITP)
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Sickle Cell Disease (SCD)
- Thalassemia
- Warm Autoimmune Hemolytic Anemia (wAIHA)
The insights that inform confident, strategic decisions
The Spherix three-perspective lens applied to hematology:
physician
How are hematologists approaching patient selection for gene therapy in SCD and beta-thalassemia? Where is prescribing intent shifting in hemophilia as rebalancing agents reshape the class?
Patient
What are patients with rare bleeding disorders reporting about treatment burden, adherence, and quality of life that is not captured in clinical trial data?
payer (market access)
How are payers approaching coverage and reimbursement for gene therapies — and what does that mean for brand teams whose patients may be eligible but unable to access?
Spherix clients have exclusive access to
Research products
Therapeutic expertise and advisory
Customization and targeting
AI-assisted synthesis
Every output is reviewed and validated by a hematology specialist before delivery. Spherix's AI-assisted intelligence layer accelerates time from data collection to insight and helps identify the right hematologists and KOLs for every wave – critical in rare-disease indications where the pool is small.
Related Articles
Meet the Team
